<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29659585</article-id><article-id pub-id-type="pmc">5901776</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0194623</article-id><article-id pub-id-type="publisher-id">PONE-D-17-32212</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Coronary Heart Disease</subject><subj-group><subject>Stable Coronary Artery Disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Cardiology</subject><subj-group><subject>Coronary Heart Disease</subject><subj-group><subject>Stable Coronary Artery Disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Cardiovascular Procedures</subject><subj-group><subject>Angioplasty</subject><subj-group><subject>Coronary Angioplasty</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>Cytoskeletal Proteins</subject><subj-group><subject>Troponin</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Surgical and Invasive Medical Procedures</subject><subj-group><subject>Cardiovascular Procedures</subject><subj-group><subject>Revascularization</subject><subj-group><subject>Coronary Revascularization</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Endocrinology</subject><subj-group><subject>Endocrine Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Metabolic Disorders</subject><subj-group><subject>Diabetes Mellitus</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Angina</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Vascular Medicine</subject><subj-group><subject>Ischemia</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Biomarkers</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Protective effect of nicorandil on myocardial injury following percutaneous coronary intervention in older patients with stable coronary artery disease: Secondary analysis of a randomized, controlled trial (RINC)</article-title><alt-title alt-title-type="running-head">Nicorandil against myocardial injury after PCI in the elderly</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kawakita</surname><given-names>Norifumi</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ejiri</surname><given-names>Kentaro</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9039-3439</contrib-id><name><surname>Miyoshi</surname><given-names>Toru</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Kohno</surname><given-names>Kunihisa</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakahama</surname><given-names>Makoto</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Doi</surname><given-names>Masayuki</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Munemasa</surname><given-names>Mitsuru</given-names></name><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Murakami</surname><given-names>Masaaki</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nakamura</surname><given-names>Kazufumi</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ito</surname><given-names>Hiroshi</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><collab>on behalf of the RINC investigators</collab><xref ref-type="author-notes" rid="fn001"><sup>&#x000b6;</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Density and Pharmaceutical Sciences, Okayama, Japan</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Cardiology, Fukuyama City Hospital, Hiroshima, Japan</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Department of Cardiology, Kagawa Prefectural Central Hospital, Kagawa, Japan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Department of Cardiology, Okayama Medical Center, Okayama, Japan</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Department of Cardiology, Okayama Heart Clinic, Okayama, Japan</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Fukumoto</surname><given-names>Yoshihiro</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Kurume University School of Medicine, JAPAN</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>TM received honorarium from Chugai Pharmaceutical Co. HI received a research grant and honorarium from Chugai Pharmaceutical Co. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><fn fn-type="other" id="fn001"><p>&#x000b6; Membership of the RINC investigators is provided in the Acknowledgments.</p></fn><corresp id="cor001">* E-mail: <email>miyoshit@cc.okayama-u.ac.jp</email></corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>4</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>13</volume><issue>4</issue><elocation-id>e0194623</elocation-id><history><date date-type="received"><day>2</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2018 Kawakita et al</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Kawakita et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0194623.pdf"/><abstract><sec id="sec001"><title>Background</title><p>Our previous study examined an effect of remote ischemic preconditioning (RIPC) or intravenous nicorandil on reduction of periprocedural myocardial injury (pMI) following percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD). We further investigated the effect of RIPC or nicorandil on pMI in older patients.</p></sec><sec id="sec002"><title>Methods</title><p>Patients with stable CAD who planned to undergo PCI were assigned to a 1:1:1 ratio to control, intravenous nicorandil, or upper-limb RIPC groups. This substudy analyzed patients aged &#x0003e;65 years (n = 282) from the principal cohort. The primary outcome was the incidence of pMI following PCI. We defined pMI as an elevated level of high-sensitive cardiac troponin T or creatine kinase myocardial band 12 or 24 hours after PCI.</p></sec><sec id="sec003"><title>Results</title><p>We found that pMI following PCI was significantly reduced in the nicorandil group compared with the control group (37.2% vs. 53.7%, multiplicity-adjusted <italic>p</italic> = 0.046), but not in the RIPC group compared with the control group (43.0% vs. 53.7%, multiplicity-adjusted <italic>p</italic> = 0.245). The adjusted odds ratios (95% confidence interval) for pMI in the RIPC and nicorandil groups versus the control group were 0.63 (0.34 to 1.16) and 0.51 (0.27 to 0.96), respectively.</p></sec><sec id="sec004"><title>Conclusion</title><p>Intravenous nicorandil significantly reduces pMI following PCI in a subgroup of older patients with stable CAD. Phase 3 trials are required to validate our results.</p></sec><sec id="sec005"><title>Trial registration</title><p>UMIN Clinical Trials Registry <ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&#x00026;action=brows&#x00026;type=summary&#x00026;recptno=R000006626&#x00026;language=E">UMIN000005607</ext-link>.</p></sec></abstract><funding-group><award-group id="award001"><funding-source><institution>Okayama Medical Foundation</institution></funding-source></award-group><funding-statement>This study was funded by the Okayama Medical Foundation, <ext-link ext-link-type="uri" xlink:href="http://omf.umin.ac.jp">http://omf.umin.ac.jp</ext-link>. TM received honorarium from Chugai Pharmaceutical Co. HI received a research grant and honorarium from Chugai Pharmaceutical Co. The funder provided support in the form of salaries for authors [TM and HI], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the &#x02018;author contributions&#x02019; section.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="14"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec006"><title>Introduction</title><p>Periprocedural myocardial injury (pMI) is a complication of elective percutaneous coronary intervention (PCI) in patients with stable coronary artery disease (CAD) and affects long-term prognosis [<xref rid="pone.0194623.ref001" ref-type="bibr">1</xref>,<xref rid="pone.0194623.ref002" ref-type="bibr">2</xref>]. The potential contributing mechanisms for pMI following elective PCI in patients with stable angina include downstream embolization of atheromatous material and coronary side-branch occlusion [<xref rid="pone.0194623.ref003" ref-type="bibr">3</xref>,<xref rid="pone.0194623.ref004" ref-type="bibr">4</xref>]. However, pMI is associated with various factors, including procedure-related, lesion-related, and patient-related factors [<xref rid="pone.0194623.ref005" ref-type="bibr">5</xref>]. Patient-related factors are involved in multivessel disease, diabetes mellitus, chronic kidney disease and older age, which increase the risk of postprocedural creatine kinase myocardial band (CK-MB) release by 1.3- to 1.8-fold. [<xref rid="pone.0194623.ref006" ref-type="bibr">6</xref>,<xref rid="pone.0194623.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0194623.ref008" ref-type="bibr">8</xref>,<xref rid="pone.0194623.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0194623.ref010" ref-type="bibr">10</xref>]</p><p>Several approaches, including remote ischemic preconditioning (RIPC) and nicorandil, have been evaluated to increase cardiac tolerance to ischemic injury following PCI [<xref rid="pone.0194623.ref011" ref-type="bibr">11</xref>,<xref rid="pone.0194623.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0194623.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0194623.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0194623.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0194623.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0194623.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0194623.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0194623.ref019" ref-type="bibr">19</xref>]. RIPC is defined as when transient nonfatal ischemia and reperfusion applied to one organ or tissue protects another organ or tissue from a subsequent episode of fatal ischemia and reperfusion [<xref rid="pone.0194623.ref020" ref-type="bibr">20</xref>]. Nicorandil activates adenosine triphosphate-sensitive potassium channels in mitochondria, and this plays a role in imitating ischemic preconditioning [<xref rid="pone.0194623.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0194623.ref022" ref-type="bibr">22</xref>,<xref rid="pone.0194623.ref023" ref-type="bibr">23</xref>].</p><p>We recently reported a multicenter, randomized trial that examined whether pre-procedural RIPC or intravenous nicorandil reduces pMI in patients who undergo elective PCI for stable CAD. This study showed that RIPC or intravenous nicorandil moderately reduced biomarker release and pMI in patients with stable CAD, but these results were not significant [<xref rid="pone.0194623.ref024" ref-type="bibr">24</xref>]. Therefore, an exploratory analysis to identify a population in whom RIPC or intravenous nicorandil is effective was planned. We hypothesized that age influences the effect of RIPC or intravenous nicorandil on pMI. This hypothesis was based on the finding that age was a predictor of pMI [<xref rid="pone.0194623.ref005" ref-type="bibr">5</xref>] and related to short-term and long-term critical events, such as death, in patients who had PCI for acute coronary syndrome [<xref rid="pone.0194623.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0194623.ref026" ref-type="bibr">26</xref>]</p><p>This study aimed to investigate the efficacy of RIPC or intravenous nicorandil on pMI in older patients with stable CAD undergoing elective PCI. This was a substudy of our previous multicenter, randomized study.</p></sec><sec sec-type="materials|methods" id="sec007"><title>Materials and methods</title><p>The protocol for this trial, supporting CONSORT checklist, and full data set are available as supporting information (see <xref ref-type="supplementary-material" rid="pone.0194623.s001">S1 CONSORT Checklist</xref>, <xref ref-type="supplementary-material" rid="pone.0194623.s002">S1 Protocol</xref> and <xref ref-type="supplementary-material" rid="pone.0194623.s003">S1 Data Set</xref>).</p><sec id="sec008"><title>Ethics statement</title><p>The study was approved by the ethics committees of all hospitals. All participants provided written informed consent before enrolling. This study was conducted according to the principles expressed in the Declaration of Helsinki. The study is registered at the UMIN Clinical Trials Registry (UMIN000005607) at <ext-link ext-link-type="uri" xlink:href="https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006626">https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006626</ext-link>. A list of investigators is provided in the Acknowledgments.</p></sec><sec id="sec009"><title>Study design</title><p>The principal study (Cardiac Preconditioning Effect of Remote Ischemia and Nicorandil in Patients Undergoing Elective Percutaneous Coronary Intervention: RINC) was a prospective, open-label, multicenter, randomized, controlled trial, which was conducted between February 2011 and January 2013 [<xref rid="pone.0194623.ref024" ref-type="bibr">24</xref>]. This was a post-hoc analysis of the RINC study. <xref ref-type="fig" rid="pone.0194623.g001">Fig 1</xref> shows a flow diagram of the study. Eligible patients were adults (&#x0003e;20 years old) who were diagnosed with stable CAD, including silent myocardial ischemia and stable angina, and planned to have elective PCI. All of the patients underwent coronary angiography before enrollment in this study. Indication of PCI was evaluated according to the guideline for elective percutaneous coronary intervention in patients with stable coronary artery disease from the Japanese Society of Cardiology [<xref rid="pone.0194623.ref027" ref-type="bibr">27</xref>]. Patients were excluded for the following reasons: they had acute coronary syndrome, there was contraindication of intravenous nicorandil administration, they planned elective PCI for chronic total occlusion lesion or PCI with a rotablator, use of sulfonylurea, an arterio-venous shunt was present in the arms, and prognosis was regarded as less than 12 months. In the principal study, we enrolled 405 patients at 18 coronary intervention centers in Japan. Among them, 396 patients underwent randomization. Using post-hoc analysis, we aimed to identify any myocardial protective effect of RIPC during elective PCI in older patients. Therefore, patients aged 65 years or younger were excluded. Finally, 282 patients were included in this post-hoc analysis (control: n = 95, nicorandil: n = 94, RIPC: n = 93).</p><fig id="pone.0194623.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194623.g001</object-id><label>Fig 1</label><caption><title>Flow diagram of the study.</title><p>PCI, percutaneous coronary intervention; RIPC, remote ischemic preconditioning.</p></caption><graphic xlink:href="pone.0194623.g001"/></fig><p>The intervention protocol and PCI procedure have been described previously [<xref rid="pone.0194623.ref024" ref-type="bibr">24</xref>]. In patients who were assigned to the nicorandil group, 4 mg of nicorandil was intravenously administered for 5 minutes for at least 1 hour before PCI, followed by continuous infusion of nicorandil (6 mg/h) for at least 8 hours. In patients who were assigned to the RIPC group, 5-minute inflation of a blood pressure cuff to 200 mmHg around the upper arm was performed. This was followed by 5-minute deflation of the cuff to 0 mmHg. This process was performed three times at least 1 hour before PCI. This procedure was automatically performed by a newly developed automated continuous blood pressure device (FB-270; Fukuda Denshi, Tokyo, Japan) [<xref rid="pone.0194623.ref028" ref-type="bibr">28</xref>]. Stopping the infusion was dependent on the practice of each hospital. Patients in the control group did not receive any additional pretreatment before PCI. PCI was performed in a conventional manner.</p><p>The primary outcome in the current study was the incidence of pMI following PCI. The definition of pMI was as follows: an elevation in high-sensitive cardiac troponin T (cTnT) levels &#x0003e;0.07 ng/ml (5&#x000d7;99th percentile upper reference limit); or CK-MB levels &#x0003e;10 ng/ml and CK-MB/creatinine kinase levels &#x0003e;5%, at 12 or 24 hours after PCI. If patients were discharged before regular assessment, these cardiac biomarkers were assessed at discharge.</p><p>The secondary outcomes in the current study were ischemic events during PCI, including chest pain during PCI, ST segment change on an electrocardiogram (&#x0003e;0.1 mV) during PCI, ventricular arrhythmia required for cardioversion during PCI, and final thrombolysis in myocardial infarction (TIMI) grade. We also studied adverse clinical events at 8 months after PCI as a secondary outcome. Adverse clinical events included cardiovascular or non-cardiovascular death, admission for acute coronary syndrome, any revascularization, and admission for heart failure.</p></sec><sec id="sec010"><title>Statistical analysis</title><p>Continuous variables are presented as mean&#x000b1;standard deviation (SD) or as median with the interquartile range. Categorical variables are presented as frequencies and proportions (%). Continuous variables were compared using analysis of variance or the Kruskal&#x02013;Wallis test for non-normally distributed parameters. Categorical variables were compared using Pearson&#x02019;s chi-square test.</p><p>Fisher&#x02019;s exact test was applied to compare proportions of pMI following PCI between the nicorandil and control or the RIPC and control groups. The <italic>p</italic> values were adjusted using the bootstrap method (1,000,000 iterations) to account for multiplicity [<xref rid="pone.0194623.ref029" ref-type="bibr">29</xref>]. The odds ratios (ORs) between groups and their 95% exact confidence intervals (CIs) were calculated. Additionally, a logistic regression model was used to calculate ORs between study groups with adjustment for sex, and with or without chronic kidney disease (estimated glomerular filtration rate [eGFR] at baseline &#x0003c;60 or &#x02265;60 ml/min/1.73 m<sup>2</sup>). The adjusted ORs between groups and their 95% exact CIs were calculated. The <italic>p</italic> values were adjusted using the Dunnett&#x02013;Hsu method to account for multiplicity. The Hosmer&#x02013;Lemeshow lack-of-fit test was also applied. The same models of the primary outcome were applied to ischemic events during PCI. For analysis of the primary outcome, we also used a mixed-effect logistic regression model in which the center ID was included as a random-intercept term to assess the robustness of the primary analysis. Sandwich estimators of the covariance matrix of regression coefficients were used for the analysis.</p><p>For adverse clinical events at 8 months after PCI, the Kaplan&#x02013;Meier estimate was used by treatment group and compared using the log-rank test. The <italic>p</italic> values were adjusted using the Dunnett&#x02013;Hsu method to account for multiplicity. The Cox proportional hazards model was used to estimate hazard ratios (HRs) and their 95% profile likelihood CIs between treatment groups. The statistical test of Lin, Wei, and Ying (1993) for checking the adequacy of proportional hazard assumption was also applied [<xref rid="pone.0194623.ref030" ref-type="bibr">30</xref>].</p><p>All analyses were performed with IBM SPSS Statistics 24.0 and SAS system 9.4. Two-tailed values of <italic>p</italic>&#x0003c;0.05 were considered statistically significant.</p></sec></sec><sec sec-type="results" id="sec011"><title>Results</title><sec id="sec012"><title>Baseline characteristics</title><p><xref ref-type="table" rid="pone.0194623.t001">Table 1</xref> shows the baseline characteristics of the patients. In patients aged &#x0003e;65 years, 50.0% of patients were diagnosed with diabetes previously. A total of 59.9% of patients were current or past smokers. Procedural characteristics were not significantly different among the groups. A total of 51.1% of patients had complex coronary lesions, such as AHA-ACC characteristics of types B2 (31.9%) and C (19.1%). Target vessels and AHA-ACC characteristics of types of lesions, and the diameter and length of stents were not significantly different among the groups. Baseline characteristics in patients aged &#x02264;65 years (n = 109) are shown in <xref ref-type="supplementary-material" rid="pone.0194623.s004">S1 Table</xref>.</p><table-wrap id="pone.0194623.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194623.t001</object-id><label>Table 1</label><caption><title>Baseline characteristics of patients aged &#x0003e;65 years.</title></caption><alternatives><graphic id="pone.0194623.t001g" xlink:href="pone.0194623.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Control group (n = 95)</th><th align="center" rowspan="1" colspan="1">RIPC group (n = 93)</th><th align="center" rowspan="1" colspan="1">Nicorandil group (n = 94)</th><th align="center" rowspan="1" colspan="1">p value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age-yr.</td><td align="center" rowspan="1" colspan="1">75.4(5.3)</td><td align="center" rowspan="1" colspan="1">75.5(5.9)</td><td align="center" rowspan="1" colspan="1">74.3(5.9)</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">Male-n (%)</td><td align="center" rowspan="1" colspan="1">69(72.6)</td><td align="center" rowspan="1" colspan="1">65(69.9)</td><td align="center" rowspan="1" colspan="1">69(73.4)</td><td align="center" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Body mass index (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">24.0(3.1)</td><td align="center" rowspan="1" colspan="1">24.0(3.5)</td><td align="center" rowspan="1" colspan="1">24.6(3.7)</td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Angina symptom-n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;symptomatic</td><td align="center" rowspan="1" colspan="1">65(68.4)</td><td align="center" rowspan="1" colspan="1">69(74.2)</td><td align="center" rowspan="1" colspan="1">71(75.5)</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;asymptomatic</td><td align="center" rowspan="1" colspan="1">30(31.6)</td><td align="center" rowspan="1" colspan="1">24(25.8)</td><td align="center" rowspan="1" colspan="1">23(24.5)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Prior diagnoses-n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diabetes Mellitus</td><td align="center" rowspan="1" colspan="1">47(49.5)</td><td align="center" rowspan="1" colspan="1">43(46.2)</td><td align="center" rowspan="1" colspan="1">51(54.3)</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hypertension</td><td align="center" rowspan="1" colspan="1">86(90.5)</td><td align="center" rowspan="1" colspan="1">81(87.1)</td><td align="center" rowspan="1" colspan="1">79(84.0)</td><td align="center" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Dyslipidemia</td><td align="center" rowspan="1" colspan="1">74(77.9)</td><td align="center" rowspan="1" colspan="1">78(83.9)</td><td align="center" rowspan="1" colspan="1">79(84.0)</td><td align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1">CCV event history-n (%)</td><td align="center" rowspan="1" colspan="1">43(45.3)</td><td align="center" rowspan="1" colspan="1">46(49.5)</td><td align="center" rowspan="1" colspan="1">44(46.8)</td><td align="center" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking history-n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Current smoker</td><td align="center" rowspan="1" colspan="1">4(4.2)</td><td align="center" rowspan="1" colspan="1">5(5.4)</td><td align="center" rowspan="1" colspan="1">7(7.4)</td><td align="center" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Ex-smoker</td><td align="center" rowspan="1" colspan="1">52(54.7)</td><td align="center" rowspan="1" colspan="1">50(53.8)</td><td align="center" rowspan="1" colspan="1">51(54.3)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Echocardiographic parameters at randomization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;LVEF (%)</td><td align="center" rowspan="1" colspan="1">61.9(10.7)</td><td align="center" rowspan="1" colspan="1">61.1(11.5)</td><td align="center" rowspan="1" colspan="1">63.5(9.0)</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;E/e</td><td align="center" rowspan="1" colspan="1">13.3(5.2)</td><td align="center" rowspan="1" colspan="1">13.2(5.2)</td><td align="center" rowspan="1" colspan="1">13.6(4.8)</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Laboratory data at randomization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hemoglobin (g/dl)</td><td align="center" rowspan="1" colspan="1">12.9(1.8)</td><td align="center" rowspan="1" colspan="1">13.0(1.7)</td><td align="center" rowspan="1" colspan="1">12.9(1.8)</td><td align="center" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Platelet count (10<sup>4</sup>/&#x003bc;l)</td><td align="center" rowspan="1" colspan="1">19.1(5.7)</td><td align="center" rowspan="1" colspan="1">20.1(6.1)</td><td align="center" rowspan="1" colspan="1">20.3(5.9)</td><td align="center" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Total cholesterol (mg/dl)</td><td align="center" rowspan="1" colspan="1">159.0[135.0&#x02013;185.3]</td><td align="center" rowspan="1" colspan="1">156.0[137.8&#x02013;173.0]</td><td align="center" rowspan="1" colspan="1">162.5[140.0&#x02013;183.5]</td><td align="center" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Serum creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">0.86[0.72&#x02013;1.0]</td><td align="center" rowspan="1" colspan="1">0.86[0.75&#x02013;1.0]</td><td align="center" rowspan="1" colspan="1">0.85[0.70&#x02013;1.1]</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;eGFR (ml/min/1.73 cm<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">63.2(15.1)</td><td align="center" rowspan="1" colspan="1">61.4(17.5)</td><td align="center" rowspan="1" colspan="1">61.3(19.1)</td><td align="center" rowspan="1" colspan="1">0.67</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Hemoglobin A1C (%)</td><td align="center" rowspan="1" colspan="1">5.9[5.3&#x02013;6.5]</td><td align="center" rowspan="1" colspan="1">5.7[5.4&#x02013;6.6]</td><td align="center" rowspan="1" colspan="1">5.9[5.4&#x02013;6.6]</td><td align="center" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;C-reactive protein (mg/dl)</td><td align="center" rowspan="1" colspan="1">0.10[0.03&#x02013;0.31]</td><td align="center" rowspan="1" colspan="1">0.10[0.04&#x02013;0.22]</td><td align="center" rowspan="1" colspan="1">0.13[0.06&#x02013;0.30]</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Brain natriuretic peptide (pg/ml)</td><td align="center" rowspan="1" colspan="1">37.0[21.4&#x02013;80.2]</td><td align="center" rowspan="1" colspan="1">61.5[18.3&#x02013;129.8]</td><td align="center" rowspan="1" colspan="1">44.2[23.6&#x02013;91.4]</td><td align="center" rowspan="1" colspan="1">0.38</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial biomarker at randomization</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Cardiac troponin T (ng/ml)</td><td align="center" rowspan="1" colspan="1">0.013[0.009&#x02013;0.019]</td><td align="center" rowspan="1" colspan="1">0.012[0.008&#x02013;0.022]</td><td align="center" rowspan="1" colspan="1">0.012[0.009&#x02013;0.020]</td><td align="center" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;CK-MB (ng/ml)</td><td align="center" rowspan="1" colspan="1">3.9[2.5&#x02013;5.2]</td><td align="center" rowspan="1" colspan="1">3.7[2.7&#x02013;4.6]</td><td align="center" rowspan="1" colspan="1">3.8[2.7&#x02013;5.0]</td><td align="center" rowspan="1" colspan="1">0.55</td></tr><tr><td align="left" rowspan="1" colspan="1">Medications at randomization-no. (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Antiplatelets</td><td align="center" rowspan="1" colspan="1">95(100)</td><td align="center" rowspan="1" colspan="1">92(98.9)</td><td align="center" rowspan="1" colspan="1">94(100)</td><td align="center" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x003b2;-blockers</td><td align="center" rowspan="1" colspan="1">31(32.6)</td><td align="center" rowspan="1" colspan="1">39(41.9)</td><td align="center" rowspan="1" colspan="1">37(39.4)</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;ACEIs/ARBs</td><td align="center" rowspan="1" colspan="1">64(67.4)</td><td align="center" rowspan="1" colspan="1">54(58.1)</td><td align="center" rowspan="1" colspan="1">57(60.6)</td><td align="center" rowspan="1" colspan="1">0.40</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Calcium channel blockers</td><td align="center" rowspan="1" colspan="1">53(55.8)</td><td align="center" rowspan="1" colspan="1">51(54.8)</td><td align="center" rowspan="1" colspan="1">43(45.7)</td><td align="center" rowspan="1" colspan="1">0.31</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Statins</td><td align="center" rowspan="1" colspan="1">71(74.7)</td><td align="center" rowspan="1" colspan="1">75(80.6)</td><td align="center" rowspan="1" colspan="1">74(78.7)</td><td align="center" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Procedure characteristics</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Target vessel-no. (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;LAD</td><td align="center" rowspan="1" colspan="1">44(46.3)</td><td align="center" rowspan="1" colspan="1">41(44.1)</td><td align="center" rowspan="1" colspan="1">37(39.4)</td><td align="center" rowspan="1" colspan="1">0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;LCX</td><td align="center" rowspan="1" colspan="1">15(15.8)</td><td align="center" rowspan="1" colspan="1">15(16.1)</td><td align="center" rowspan="1" colspan="1">25(26.6)</td><td align="center" rowspan="1" colspan="1">0.10</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;RCA</td><td align="center" rowspan="1" colspan="1">31(32.6)</td><td align="center" rowspan="1" colspan="1">32(34.4)</td><td align="center" rowspan="1" colspan="1">29(30.9)</td><td align="center" rowspan="1" colspan="1">0.87</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;multiple</td><td align="center" rowspan="1" colspan="1">5(5.3)</td><td align="center" rowspan="1" colspan="1">5(5.4)</td><td align="center" rowspan="1" colspan="1">3(3.2)</td><td align="center" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">AHA-ACC classification-no. (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Type A</td><td align="center" rowspan="1" colspan="1">14(14.7)</td><td align="center" rowspan="1" colspan="1">15(16.1)</td><td align="center" rowspan="1" colspan="1">15(16.0)</td><td align="center" rowspan="1" colspan="1">0.97</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Type B1</td><td align="center" rowspan="1" colspan="1">35(36.8)</td><td align="center" rowspan="1" colspan="1">31(33.3)</td><td align="center" rowspan="1" colspan="1">28(29.8)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Type B2</td><td align="center" rowspan="1" colspan="1">25(26.3)</td><td align="center" rowspan="1" colspan="1">30(32.3)</td><td align="center" rowspan="1" colspan="1">35(37.2)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Type C</td><td align="center" rowspan="1" colspan="1">21(22.1)</td><td align="center" rowspan="1" colspan="1">17(18.3)</td><td align="center" rowspan="1" colspan="1">16(17.0)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Amount of contrast medium (ml)</td><td align="center" rowspan="1" colspan="1">104.3(37.7)</td><td align="center" rowspan="1" colspan="1">105.7(50.4)</td><td align="center" rowspan="1" colspan="1">106.7(45.6)</td><td align="center" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Puncture site, n/total n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Radial artery</td><td align="center" rowspan="1" colspan="1">55/95(57.9)</td><td align="center" rowspan="1" colspan="1">51/92(55.4)<xref ref-type="table-fn" rid="t001fn002">*</xref></td><td align="center" rowspan="1" colspan="1">57/94(60.6)</td><td align="center" rowspan="1" colspan="1">0.88</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Brachial artery</td><td align="center" rowspan="1" colspan="1">13/95(13.7)</td><td align="center" rowspan="1" colspan="1">12/92(13.0)<xref ref-type="table-fn" rid="t001fn002">*</xref></td><td align="center" rowspan="1" colspan="1">14/94(14.9)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Femoral artery</td><td align="center" rowspan="1" colspan="1">27/95(28.4)</td><td align="center" rowspan="1" colspan="1">29/92(31.5)<xref ref-type="table-fn" rid="t001fn002">*</xref></td><td align="center" rowspan="1" colspan="1">23/94(24.5)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Catheter size, n/total n (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;6 Fr</td><td align="center" rowspan="1" colspan="1">82/95(86.3)</td><td align="center" rowspan="1" colspan="1">76/91(83.5)<xref ref-type="table-fn" rid="t001fn003">**</xref></td><td align="center" rowspan="1" colspan="1">87/94(92.6)</td><td align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;7 Fr</td><td align="center" rowspan="1" colspan="1">11/95(11.6)</td><td align="center" rowspan="1" colspan="1">15/91(16.5)<xref ref-type="table-fn" rid="t001fn003">**</xref></td><td align="center" rowspan="1" colspan="1">7/94(7.4)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;8 Fr</td><td align="center" rowspan="1" colspan="1">2/95(2.1)</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Details of device</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;No. of stents used</td><td align="center" rowspan="1" colspan="1">1[1&#x02013;2]</td><td align="center" rowspan="1" colspan="1">1[1&#x02013;2]</td><td align="center" rowspan="1" colspan="1">1[1&#x02013;2]</td><td align="center" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Drug-eluting stent, n/total n (%)</td><td align="center" rowspan="1" colspan="1">123/133(92.5)</td><td align="center" rowspan="1" colspan="1">113/120(94.2)</td><td align="center" rowspan="1" colspan="1">114/123(92.7)</td><td align="center" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Stent diameter (mm)</td><td align="center" rowspan="1" colspan="1">2.75[2.5&#x02013;3.5]</td><td align="center" rowspan="1" colspan="1">3[2.5&#x02013;3.5]</td><td align="center" rowspan="1" colspan="1">3[2.5&#x02013;3]</td><td align="center" rowspan="1" colspan="1">0.20</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Stent length (mm)</td><td align="center" rowspan="1" colspan="1">18[15&#x02013;24]</td><td align="center" rowspan="1" colspan="1">20[15&#x02013;28]</td><td align="center" rowspan="1" colspan="1">20[15&#x02013;24]</td><td align="center" rowspan="1" colspan="1">0.33</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Stent inflation time (second)</td><td align="center" rowspan="1" colspan="1">15[10&#x02013;20]</td><td align="center" rowspan="1" colspan="1">15[10&#x02013;20]</td><td align="center" rowspan="1" colspan="1">15[10&#x02013;20]</td><td align="center" rowspan="1" colspan="1">0.26</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Post dilation (%)</td><td align="center" rowspan="1" colspan="1">74/95(77.9)</td><td align="center" rowspan="1" colspan="1">70/93(75.3)</td><td align="center" rowspan="1" colspan="1">63/94(67.0)</td><td align="center" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Post dilation time (second)</td><td align="center" rowspan="1" colspan="1">15[10&#x02013;30]</td><td align="center" rowspan="1" colspan="1">20[15&#x02013;30]</td><td align="center" rowspan="1" colspan="1">15[10&#x02013;40]</td><td align="center" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Maximum dilatation pressure (atm)</td><td align="center" rowspan="1" colspan="1">16.4(4.4)</td><td align="center" rowspan="1" colspan="1">17.4(4.3)</td><td align="center" rowspan="1" colspan="1">16.6(4.5)</td><td align="center" rowspan="1" colspan="1">0.29</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>Data are mean (standard deviation), n (%), or median [interquartile range]. RIPC, remote ischemic preconditioning; CCV, cardio-cerebrovascular; LVEF, left ventricular ejection fraction; E, peak velocity of the early diastolic filling wave; e&#x02032;, mitral annulus velocity; eGFR, estimated glomerular filtration rate; CK, creatine kinase; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; LAD, left anterior descending artery; LCX, left circumflex artery; RCA, right coronary artery; AHA, American Heart Association; ACC, American College of Cardiology; Fr, French; atm, atmospheres.</p></fn><fn id="t001fn002"><p>*One patient&#x02019;s data were uncollected</p></fn><fn id="t001fn003"><p>**two patients&#x02019; data were uncollected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec013"><title>Primary outcome</title><p>The incidence of pMI following PCI in the nicorandil group (35/94, 37.2%) was significantly lower than that in the control group (51/95, 53.7%) (<xref ref-type="fig" rid="pone.0194623.g002">Fig 2</xref>). However, the incidence of pMI was not significantly different between the RIPC and control groups (40/93, 43.0%). In adjusted analysis, the risk reduction remained significant between the control and nicorandil groups (adjusted OR: 0.51; 95% CI: 0.27 to 0.96; multiplicity-adjusted <italic>p</italic> = 0.045) (<xref ref-type="table" rid="pone.0194623.t002">Table 2</xref>). However, the incidence of pMI was not significantly different between the control and RIPC groups (adjusted OR: 0.63; 95% CI: 0.34 to 1.16; multiplicity-adjusted <italic>p</italic> = 0.196). In mixed-effect logistic regression analysis, the incidence of pMI was also significantly different between the control and nicorandil groups (OR: 0.50; 95% CI: 0.31 to 0.82; multiplicity-adjusted <italic>p</italic> = 0.010). However, the incidence of pMI was not significantly different between the control and RIPC groups (OR: 0.65; 95% CI: 0.41 to 1.03; multiplicity-adjusted <italic>p</italic> = 0.119). The <italic>p</italic> values in Hosmer&#x02013;Lemeshow lack-of-fit tests were non-significant. In patients aged &#x02264;65 years, the incidence of pMI in the nicorandil group (17/35, 48.6%) and in the RIPC group (11/36, 30.6%) was not significantly different compared with that in the control group (14/38, 36.8%) (multiplicity-adjusted <italic>p</italic> = 0.511 and multiplicity-adjusted <italic>p</italic> = 0.745, respectively) (<xref ref-type="supplementary-material" rid="pone.0194623.s005">S1 Fig</xref>).</p><fig id="pone.0194623.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194623.g002</object-id><label>Fig 2</label><caption><title>Incidence of periprocedural myocardial injury in patients aged &#x0003e;65 years.</title><p>pMI, periprocedural myocardial injury; RIPC, remote ischemic preconditioning.</p></caption><graphic xlink:href="pone.0194623.g002"/></fig><table-wrap id="pone.0194623.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194623.t002</object-id><label>Table 2</label><caption><title>Odds ratios for primary and secondary outcomes in patients aged &#x0003e;65 years.</title></caption><alternatives><graphic id="pone.0194623.t002g" xlink:href="pone.0194623.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Control group</th><th align="center" rowspan="1" colspan="1">RIPC group</th><th align="center" rowspan="1" colspan="1">RIPC vs. Control (reference)</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Nicorandil group</th><th align="center" rowspan="1" colspan="1">Nicorandil vs. Control (reference)</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Lack-of-fit test</th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">n = 95</th><th align="center" rowspan="1" colspan="1">n = 93</th><th align="center" rowspan="1" colspan="1">OR/HR (95% CI)</th><th align="center" rowspan="1" colspan="1">Multiplicity-adjusted p-value</th><th align="center" rowspan="1" colspan="1">n = 94</th><th align="center" rowspan="1" colspan="1">OR/HR (95% CI)</th><th align="center" rowspan="1" colspan="1">Multiplicity-adjusted p-value</th><th align="center" rowspan="1" colspan="1">p value<break/></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><bold>Primary end point</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Perioperative myocardial injury, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Unadjusted analysis<xref ref-type="table-fn" rid="t002fn002"><sup>a</sup></xref></td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">0.65</td><td align="center" rowspan="1" colspan="1">0.245</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">0.046</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">(53.7)</td><td align="center" rowspan="1" colspan="1">(43.0)</td><td align="center" rowspan="1" colspan="1">(0.35&#x02013;1.20)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(37.2)</td><td align="center" rowspan="1" colspan="1">(0.27&#x02013;0.95)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Adjusted analysis<xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="left" rowspan="2" colspan="1"/><td align="left" rowspan="2" colspan="1"/><td align="center" rowspan="1" colspan="1">0.63</td><td align="center" rowspan="1" colspan="1">0.196</td><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.51</td><td align="center" rowspan="1" colspan="1">0.045</td><td align="center" rowspan="1" colspan="1">0.861</td></tr><tr><td align="center" rowspan="1" colspan="1">(0.34&#x02013;1.16)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(0.27&#x02013;0.96)</td><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><bold>Secondary end points</bold></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic events during PCI, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Chest pain during PCI</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">1.17</td><td align="center" rowspan="1" colspan="1">0.844</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">0.7</td><td align="center" rowspan="1" colspan="1">0.558</td><td align="center" rowspan="1" colspan="1">0.842</td></tr><tr><td align="center" rowspan="1" colspan="1">(14.7)</td><td align="center" rowspan="1" colspan="1">(17.4)<xref ref-type="table-fn" rid="t002fn005">*</xref></td><td align="center" rowspan="1" colspan="1">(0.49&#x02013;2.82) <xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(10.6)</td><td align="center" rowspan="1" colspan="1">(0.26&#x02013;1.82) <xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">ST segment change on an electrocardiogram</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">1.5</td><td align="center" rowspan="1" colspan="1">0.388</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">1.01</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="1" colspan="1">0.335</td></tr><tr><td align="center" rowspan="1" colspan="1">(14.7)</td><td align="center" rowspan="1" colspan="1">(20.7)<xref ref-type="table-fn" rid="t002fn005">*</xref></td><td align="center" rowspan="1" colspan="1">(0.66&#x02013;3.49) <xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(14.9)</td><td align="center" rowspan="1" colspan="1">(0.42&#x02013;2.45) <xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Ventricular arrhythmia needed for cardioversion</td><td align="center" rowspan="2" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0<xref ref-type="table-fn" rid="t002fn005">*</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(1.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Final TIMI grade, n /total n and (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">TIMI 3</td><td align="center" rowspan="1" colspan="1">95/95</td><td align="center" rowspan="1" colspan="1">88/90</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">91/94</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">(100)</td><td align="center" rowspan="1" colspan="1">(97.8)<xref ref-type="table-fn" rid="t002fn006">**</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(96.8)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">TIMI 0&#x02013;2</td><td align="center" rowspan="2" colspan="1">0</td><td align="center" rowspan="1" colspan="1">2/90</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">3/94</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1">(2.2)<xref ref-type="table-fn" rid="t002fn006">**</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(3.2)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Adverse clinical events for 8 months after PCI, n /total n and (%)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Total</td><td align="center" rowspan="1" colspan="1">8/95</td><td align="center" rowspan="1" colspan="1">7/92</td><td align="center" rowspan="1" colspan="1">0.87</td><td align="center" rowspan="1" colspan="1">0.955</td><td align="center" rowspan="1" colspan="1">11/94</td><td align="center" rowspan="1" colspan="1">1.38</td><td align="center" rowspan="1" colspan="1">0.685</td><td align="center" rowspan="2" colspan="1">RIPC: 0.731, Nicorandil: 0.802</td></tr><tr><td align="center" rowspan="1" colspan="1">(10.4)&#x000a0;</td><td align="center" rowspan="1" colspan="1">(8.1)<xref ref-type="table-fn" rid="t002fn005">*</xref></td><td align="center" rowspan="1" colspan="1">(0.31&#x02013;2.42)<xref ref-type="table-fn" rid="t002fn004"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(12.5)</td><td align="center" rowspan="1" colspan="1">(0.56&#x02013;3.57)<xref ref-type="table-fn" rid="t002fn004"><sup>c</sup></xref></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">All-cause death</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Admission for ACS</td><td align="center" rowspan="2" colspan="1">0</td><td align="center" rowspan="2" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2/94</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(2.1)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Revascularization</td><td align="center" rowspan="1" colspan="1">6/95</td><td align="center" rowspan="1" colspan="1">3/92</td><td align="center" rowspan="1" colspan="1">0.49</td><td align="center" rowspan="1" colspan="1">0.536</td><td align="center" rowspan="1" colspan="1">7/94</td><td align="center" rowspan="1" colspan="1">1.16</td><td align="center" rowspan="1" colspan="1">0.937</td><td align="center" rowspan="2" colspan="1">RIPC: 0.905, Nicorandil: 0.488</td></tr><tr><td align="center" rowspan="1" colspan="1">(8.2)</td><td align="center" rowspan="1" colspan="1">(3.8)<xref ref-type="table-fn" rid="t002fn005">*</xref></td><td align="center" rowspan="1" colspan="1">(0.10&#x02013;1.86)<xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(8.6)</td><td align="center" rowspan="1" colspan="1">(0.39&#x02013;3.60)<xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Admission for heart failure</td><td align="center" rowspan="1" colspan="1">2/95</td><td align="center" rowspan="1" colspan="1">3/92</td><td align="center" rowspan="1" colspan="1">1.51</td><td align="center" rowspan="1" colspan="1">0.851</td><td align="center" rowspan="1" colspan="1">2/94</td><td align="center" rowspan="1" colspan="1">1.02</td><td align="center" rowspan="1" colspan="1">1.000</td><td align="center" rowspan="2" colspan="1">RIPC: 0.771, Nicorandil: 0.617</td></tr><tr><td align="center" rowspan="1" colspan="1">(2.4)</td><td align="center" rowspan="1" colspan="1">(3.3)<xref ref-type="table-fn" rid="t002fn005">*</xref></td><td align="center" rowspan="1" colspan="1">(0.25&#x02013;11.49)<xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(2.2)</td><td align="center" rowspan="1" colspan="1">(0.12&#x02013;8.48)<xref ref-type="table-fn" rid="t002fn003"><sup>b</sup></xref></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Stroke</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">1/92</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">(1.2)<xref ref-type="table-fn" rid="t002fn005">*</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>RIPC, remote ischemic preconditioning; OR, odds ratio; HR, hazard ratio; CI, confidence interval; TIMI, thrombolysis in myocardial infarction; ACS, acute coronary syndrome.</p></fn><fn id="t002fn002"><p><sup>a</sup>Fisher&#x02019;s exact test was used to calculate <italic>p</italic> values. The resulting <italic>p</italic> values were multiplicity-adjusted. Exact 95% CIs for the ORs were also calculated.</p></fn><fn id="t002fn003"><p><sup>b</sup>A logistic regression model was used to calculate ORs between study groups with adjustment for sex, and with or without chronic kidney disease (baseline eGFR &#x0003c;60 or &#x02265;60 ml/min/1.73 m<sup>2</sup>) in perioperative myocardial injury and ischemic events during PCI. The resulting p values were multiplicity-adjusted. Exact 95% CIs for the ORs were also calculated.</p></fn><fn id="t002fn004"><p><sup>c</sup>The log-rank test was used to calculate <italic>p</italic> values. The resulting <italic>p</italic> values were multiplicity-adjusted. The Cox proportional hazards model was used to estimate HRs between treatment groups for adverse clinical events for 8 months after PCI. Profile likelihood 95% CIs for the HRs were also calculated.</p></fn><fn id="t002fn005"><p>*One patient&#x02019;s data were uncollected</p></fn><fn id="t002fn006"><p>**three patients&#x02019; data were uncollected.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec014"><title>Secondary outcomes</title><p>During PCI, few ischemic events occurred in each group. The incidence of each event (chest pain during PCI, ST segment change on an electrocardiogram [&#x0003e;0.1 mV] during PCI, ventricular arrhythmia required for cardioversion during PCI, and final TIMI grade) was not significantly different among the control, nicorandil, and RIPC groups (<xref ref-type="table" rid="pone.0194623.t002">Table 2</xref>).</p><p>As shown in <xref ref-type="fig" rid="pone.0194623.g003">Fig 3</xref>, Kaplan&#x02013;Meier estimates by the log-rank test for adverse clinical events at 8 months after PCI were not significantly different between the control and nicorandil groups (11/94 [12.5%]; multiplicity-adjusted <italic>p</italic> = 0.685), or between the control and RIPC groups (8/95 [10.4%] vs. 7/92 [8.1%]; multiplicity-adjusted <italic>p</italic> = 0.955). Furthermore, in Cox regression analysis in the older cohorts, the incidence of adverse clinical events at 8 months after PCI was not significantly different between the control and nicorandil groups (HR: 1.38; 95% CI: 0.56 to 3.57), or between the control and RIPC groups (HR: 0.87; 95% CI: 0.31 to 2.42) (<xref ref-type="table" rid="pone.0194623.t002">Table 2</xref>).</p><fig id="pone.0194623.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0194623.g003</object-id><label>Fig 3</label><caption><title>Incidence of MACCE in patients aged &#x0003e; 65 years.</title><p>MACCE included cardiovascular or non-cardiovascular death, admission for acute coronary syndrome, any revascularization, and admission for heart failure. MACCE, major adverse cardiac or cerebrovascular events; RIPC, remote ischemic preconditioning.</p></caption><graphic xlink:href="pone.0194623.g003"/></fig></sec></sec><sec sec-type="conclusions" id="sec015"><title>Discussion</title><p>In this post-hoc analysis of a multicenter, randomized controlled trial, we demonstrated that intravenous nicorandil significantly reduced the incidence of pMI following PCI in older patients with stable CAD compared with the control group. However, RIPC failed to show a significant reduction in pMI. Nicorandil or RIPC did not reduce ischemic complications during elective PCI and clinical adverse events within 8 months after PCI, similar to the principal study [<xref rid="pone.0194623.ref024" ref-type="bibr">24</xref>].</p><p>This sub-analysis showed a significant effect of intravenous nicorandil on pMI in older patients with stable CAD. However, in sub-analysis of patients aged &#x02264;65 years, the incidence of pMI was not significantly different between the nicorandil and control groups. In patients with advanced age, microvascular function is considered to be impaired [<xref rid="pone.0194623.ref031" ref-type="bibr">31</xref>]. Nicorandil is a unique hybrid pharmacological agent of an adenosine triphosphate-sensitive potassium channel opener and nicotinamide nitrate. Therefore, an explanation for the beneficial effect of nicorandil is that nicorandil might compensate for a decline in cardiac mitochondrial function and ability of nitric oxide production in older patients. Notably, the route of nicorandil administration was different among previous studies. Single-center studies showed that intravenous nicorandil reduced pMI or the slow flow phenomenon following PCI in patients who had elective and emergent PCI [<xref rid="pone.0194623.ref015" ref-type="bibr">15</xref>,<xref rid="pone.0194623.ref016" ref-type="bibr">16</xref>,<xref rid="pone.0194623.ref032" ref-type="bibr">32</xref>,<xref rid="pone.0194623.ref033" ref-type="bibr">33</xref>]. However, the effect of intracoronary nicorandil is controversial [<xref rid="pone.0194623.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0194623.ref018" ref-type="bibr">18</xref>,<xref rid="pone.0194623.ref019" ref-type="bibr">19</xref>]. In our study, intravenous nicorandil administration before and after PCI might have increased tissue concentrations of nicorandil before PCI, and this could have contributed to the protective effect against pMI.</p><p>This sub-analysis also showed that pre-procedural upper limb RIPC moderately, but not significantly, reduced pMI in older patients with stable CAD. There are several possible reasons for this lack of significance. One reason is the small sample size of this sub-analysis. This sub-analysis might not have been sufficiently powered for differences that we expected, similar to our previous study. Another reason for this lack of significance could be an influence of age on the effect of RIPC. A meta-analysis showed that age was negatively correlated with a reduction in acute kidney injury by RIPC [<xref rid="pone.0194623.ref034" ref-type="bibr">34</xref>]. Therefore, various comorbidities and/or confounders could influence the effect of RIPC on target organs. However, further study to identify the populations who benefit from RIPC is warranted because RIPC is easily delivered, safe, and has a low cost.</p><p>The present study also showed that the overall incidence of pMI was 43.3% as determined with cardiac troponin T and 30.1% as determined with CK-MB. In line with our results, previous studies have shown that the incidence of pMI following elective PCI determined with cardiac troponin is higher than that determined with CK-MB when using the cut-off established by the Third Universal Definition of Myocardial Infarction [<xref rid="pone.0194623.ref035" ref-type="bibr">35</xref>]. For example, Li et al. [<xref rid="pone.0194623.ref036" ref-type="bibr">36</xref>] reported that the incidence of elevated biomarkers after elective PCI in patients with stable angina pectoris using the defined cut-off (&#x0003e;5&#x000d7; the upper reference limit) was 32.9% using cardiac troponin T and 14.5% using CK-MB. The present study demonstrated that the incidence of pMI in the control group was 53.7% based on the Third Universal Definition of Myocardial Infarction [<xref rid="pone.0194623.ref035" ref-type="bibr">35</xref>], which was relatively higher that that in other studies (15%&#x02013;63%) [<xref rid="pone.0194623.ref013" ref-type="bibr">13</xref>,<xref rid="pone.0194623.ref025" ref-type="bibr">25</xref>,<xref rid="pone.0194623.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0194623.ref029" ref-type="bibr">29</xref>,<xref rid="pone.0194623.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0194623.ref037" ref-type="bibr">37</xref>,<xref rid="pone.0194623.ref038" ref-type="bibr">38</xref>,<xref rid="pone.0194623.ref039" ref-type="bibr">39</xref>,<xref rid="pone.0194623.ref040" ref-type="bibr">40</xref>,<xref rid="pone.0194623.ref041" ref-type="bibr">41</xref>]. Several factors in our study may explain the high incidence of pMI. First, the present study included patients aged &#x0003e;65 years. Older age is an important patient-related risk factor for pMI [<xref rid="pone.0194623.ref005" ref-type="bibr">5</xref>]. Second, the higher prevalence of diabetes mellitus (53.5%) in our study than previous studies may have been associated with the higher presence of lipid-rich plaques at target lesions. This could lead to distal embolization of atheromatous material or occlusion of small side branches despite angiographic success. In fact, the highest reported incidence of pMI was 63% in patients with diabetes mellitus [<xref rid="pone.0194623.ref041" ref-type="bibr">41</xref>]. This difference in risk factors in the populations of different studies could have resulted in the greater incidence of pMI in our study.</p><p>This study has several limitations. First, this study was a post-hoc analysis of a randomized, controlled trial. Although the RINC study was a large randomized, controlled trial of RIPC in patients with elective PCI, the study sample size was relatively small because of subgroup analysis. A small sample size might have resulted in low statistical power in analysis of intravenous RIPC in this study. Second, this sub-analysis attempted to compare the nicorandil and RIPC groups separately with the control group. However, two treatment comparisons (i.e., nicorandil vs. control and RIPC vs. control) were not independent because of the same control group. Therefore, we should not consider the study results as separate independent comparisons of the two forms of treatment (nicorandil and RIPC). Third, data regarding side branch occlusion, which is one of the causes of pMI during PCI, were not available in the current study. Although final TIMI grades did not differ among treatment groups, side branch occlusion may have affected the result of this sub-analysis.</p></sec><sec sec-type="conclusions" id="sec016"><title>Conclusions</title><p>In conclusion, in this secondary analysis of the RINC study, periprocedural intravenous nicorandil significantly reduced the incidence of pMI in older patients with stable CAD. Our study suggests that intravenous nicorandil is effective in myocardial protection for stable PCI in these patients. Further investigation using a multicenter, prospective study is required to evaluate the effect of nicorandil on pMI following PCI in older patients.</p></sec><sec sec-type="supplementary-material" id="sec017"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0194623.s001"><label>S1 CONSORT Checklist</label><caption><p>(DOC)</p></caption><media xlink:href="pone.0194623.s001.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194623.s002"><label>S1 Protocol</label><caption><p>(DOC)</p></caption><media xlink:href="pone.0194623.s002.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194623.s003"><label>S1 Data Set</label><caption><title>Full data set.</title><p>(XLSX)</p></caption><media xlink:href="pone.0194623.s003.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194623.s004"><label>S1 Table</label><caption><title>Baseline characteristics of patients aged &#x02264;65 years.</title><p>(DOCX)</p></caption><media xlink:href="pone.0194623.s004.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0194623.s005"><label>S1 Fig</label><caption><title>Incidence of periprocedural myocardial injury in patients aged &#x02264;65 years.</title><p>(TIF)</p></caption><media xlink:href="pone.0194623.s005.TIF"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We thank the RINC collaborators, in addition to the authors, Yusuke Kawai (Department of Cardiology, Okayama City General Medical Center, Okayama, Japan), Tetsuya Sato (Department of Cardiology, Japanese Red Cross Okayama Hospital, Okayama, Japan), Katsumasa Sato (Department of Cardiology, Fukuyama Cardiovascular Hospital, Hiroshima, Japan), Takefumi Oka (Department of Cardiology, Tsuyama chuo Hospital, Okayama, Japan), Natsuki Takahashi (Department of Cardiology, Matsuyama Shimin Hospital, Ehime, Japan), Satoru Sakuragi (Department of Cardiology, Iwakuni Medical Center, Yamaguchi, Japan), Atsushi Mima (Department of Cardiology, Saiseikai Imabari Hospital, Ehime, Japan), Kenki Enko (Department of Cardiology, Onomichi Municipal Hospital, Hiroshima, Japan), Shingo Hosogi (Department of Cardiology, Kochi Medical Center, Kochi, Japan), Seiji Nanba (Department of Cardiology, Okayama Rosai Hospital, Okayama, Japan), and Ryoichi Hirami (Department of Cardiology, Japanese Red Cross Himeji Hospital, Hyogo, Japan). Hiroshi Ito (<email>itomd@md.okayama-u.ac.jp</email>) is a lead author for the RINC investigators.</p><p>We thank Miyuki Fujiwara and Masayo Ohmori for their technical assistance. We thank Ellen Knapp, PhD, from Edanz Group (<ext-link ext-link-type="uri" xlink:href="http://www.edanzediting.com/ac">www.edanzediting.com/ac</ext-link>) for editing a draft of this manuscript.</p></ack><ref-list><title>References</title><ref id="pone.0194623.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Kizer</surname><given-names>J</given-names></name> (<year>2003</year>) <article-title>Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention</article-title>. <source>European Heart Journal</source>
<volume>24</volume>: <fpage>1314</fpage>&#x02013;<lpage>1322</lpage>. <pub-id pub-id-type="pmid">12871688</pub-id></mixed-citation></ref><ref id="pone.0194623.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Feldman</surname><given-names>DN</given-names></name>, <name><surname>Kim</surname><given-names>L</given-names></name>, <name><surname>Rene</surname><given-names>AG</given-names></name>, <name><surname>Minutello</surname><given-names>RM</given-names></name>, <name><surname>Bergman</surname><given-names>G</given-names></name>, <name><surname>Wong</surname><given-names>SC</given-names></name> (<year>2011</year>) <article-title>Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis</article-title>. <source>Catheter Cardiovasc Interv</source>
<volume>77</volume>: <fpage>1020</fpage>&#x02013;<lpage>1030</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ccd.22962">10.1002/ccd.22962</ext-link></comment>
<pub-id pub-id-type="pmid">21574239</pub-id></mixed-citation></ref><ref id="pone.0194623.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Heusch</surname><given-names>G</given-names></name>, <name><surname>Kleinbongard</surname><given-names>P</given-names></name>, <name><surname>Bose</surname><given-names>D</given-names></name>, <name><surname>Levkau</surname><given-names>B</given-names></name>, <name><surname>Haude</surname><given-names>M</given-names></name>, <name><surname>Schulz</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Coronary microembolization: from bedside to bench and back to bedside</article-title>. <source>Circulation</source>
<volume>120</volume>: <fpage>1822</fpage>&#x02013;<lpage>1836</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.109.888784">10.1161/CIRCULATIONAHA.109.888784</ext-link></comment>
<pub-id pub-id-type="pmid">19884481</pub-id></mixed-citation></ref><ref id="pone.0194623.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Selvanayagam</surname><given-names>JB</given-names></name>, <name><surname>Porto</surname><given-names>I</given-names></name>, <name><surname>Channon</surname><given-names>K</given-names></name>, <name><surname>Petersen</surname><given-names>SE</given-names></name>, <name><surname>Francis</surname><given-names>JM</given-names></name>, <name><surname>Neubauer</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Troponin elevation after percutaneous coronary intervention directly represents the extent of irreversible myocardial injury: insights from cardiovascular magnetic resonance imaging</article-title>. <source>Circulation</source>
<volume>111</volume>: <fpage>1027</fpage>&#x02013;<lpage>1032</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/01.CIR.0000156328.28485.AD">10.1161/01.CIR.0000156328.28485.AD</ext-link></comment>
<pub-id pub-id-type="pmid">15723982</pub-id></mixed-citation></ref><ref id="pone.0194623.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Lansky</surname><given-names>AJ</given-names></name>, <name><surname>Stone</surname><given-names>GW</given-names></name> (<year>2010</year>) <article-title>Periprocedural myocardial infarction: prevalence, prognosis, and prevention</article-title>. <source>Circ Cardiovasc Interv</source>
<volume>3</volume>: <fpage>602</fpage>&#x02013;<lpage>610</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCINTERVENTIONS.110.959080">10.1161/CIRCINTERVENTIONS.110.959080</ext-link></comment>
<pub-id pub-id-type="pmid">21156928</pub-id></mixed-citation></ref><ref id="pone.0194623.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Fuchs</surname><given-names>S</given-names></name>, <name><surname>Kornowski</surname><given-names>R</given-names></name>, <name><surname>Mehran</surname><given-names>R</given-names></name>, <name><surname>Satler</surname><given-names>LF</given-names></name>, <name><surname>Pichard</surname><given-names>AD</given-names></name>, <name><surname>Kent</surname><given-names>KM</given-names></name>, <etal>et al</etal> (<year>1999</year>) <article-title>Cardiac troponin I levels and clinical outcomes in patients with acute coronary syndromes: the potential role of early percutaneous revascularization</article-title>. <source>Journal of the American College of Cardiology</source>
<volume>34</volume>: <fpage>1704</fpage>&#x02013;<lpage>1710</lpage>. <pub-id pub-id-type="pmid">10577560</pub-id></mixed-citation></ref><ref id="pone.0194623.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Thygesen</surname><given-names>K</given-names></name>, <name><surname>Alpert</surname><given-names>JS</given-names></name>, <name><surname>White</surname><given-names>HD</given-names></name>, <name><surname>Jaffe</surname><given-names>AS</given-names></name>, <name><surname>Apple</surname><given-names>FS</given-names></name>, <name><surname>Galvani</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Universal definition of myocardial infarction</article-title>. <source>Circulation</source>
<volume>116</volume>: <fpage>2634</fpage>&#x02013;<lpage>2653</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.107.187397">10.1161/CIRCULATIONAHA.107.187397</ext-link></comment>
<pub-id pub-id-type="pmid">17951284</pub-id></mixed-citation></ref><ref id="pone.0194623.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>AH</given-names></name>, <name><surname>Smith</surname><given-names>A</given-names></name>, <name><surname>Christenson</surname><given-names>RH</given-names></name>, <name><surname>Murakami</surname><given-names>MM</given-names></name>, <name><surname>Apple</surname><given-names>FS</given-names></name> (<year>2004</year>) <article-title>Evaluation of a point-of-care assay for cardiac markers for patients suspected of acute myocardial infarction</article-title>. <source>Clinica chimica acta; international journal of clinical chemistry</source>
<volume>346</volume>: <fpage>211</fpage>&#x02013;<lpage>219</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cccn.2004.03.036">10.1016/j.cccn.2004.03.036</ext-link></comment>
<pub-id pub-id-type="pmid">15256323</pub-id></mixed-citation></ref><ref id="pone.0194623.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Piran</surname><given-names>U</given-names></name>, <name><surname>Kohn</surname><given-names>DW</given-names></name>, <name><surname>Uretsky</surname><given-names>LS</given-names></name>, <name><surname>Bernier</surname><given-names>D</given-names></name>, <name><surname>Barlow</surname><given-names>EH</given-names></name>, <name><surname>Niswander</surname><given-names>CA</given-names></name>, <etal>et al</etal> (<year>1987</year>) <article-title>Immunochemiluminometric assay of creatine kinase MB with a monoclonal antibody to the MB isoenzyme</article-title>. <source>Clinical chemistry</source>
<volume>33</volume>: <fpage>1517</fpage>&#x02013;<lpage>1520</lpage>. <pub-id pub-id-type="pmid">3304711</pub-id></mixed-citation></ref><ref id="pone.0194623.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Roe</surname><given-names>MT</given-names></name>, <name><surname>Mahaffey</surname><given-names>KW</given-names></name>, <name><surname>Kilaru</surname><given-names>R</given-names></name>, <name><surname>Alexander</surname><given-names>JH</given-names></name>, <name><surname>Akkerhuis</surname><given-names>KM</given-names></name>, <name><surname>Simoons</surname><given-names>ML</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes</article-title>. <source>European heart journal</source>
<volume>25</volume>: <fpage>313</fpage>&#x02013;<lpage>321</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ehj.2003.12.009">10.1016/j.ehj.2003.12.009</ext-link></comment>
<pub-id pub-id-type="pmid">14984920</pub-id></mixed-citation></ref><ref id="pone.0194623.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Zografos</surname><given-names>TA</given-names></name>, <name><surname>Katritsis</surname><given-names>GD</given-names></name>, <name><surname>Tsiafoutis</surname><given-names>I</given-names></name>, <name><surname>Bourboulis</surname><given-names>N</given-names></name>, <name><surname>Katsivas</surname><given-names>A</given-names></name>, <name><surname>Katritsis</surname><given-names>DG</given-names></name> (<year>2014</year>) <article-title>Effect of one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous coronary intervention</article-title>. <source>Am J Cardiol</source>
<volume>113</volume>: <fpage>2013</fpage>&#x02013;<lpage>2017</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjcard.2014.03.043">10.1016/j.amjcard.2014.03.043</ext-link></comment>
<pub-id pub-id-type="pmid">24793669</pub-id></mixed-citation></ref><ref id="pone.0194623.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Ahmed</surname><given-names>RM</given-names></name>, <name><surname>Mohamed el</surname><given-names>HA</given-names></name>, <name><surname>Ashraf</surname><given-names>M</given-names></name>, <name><surname>Maithili</surname><given-names>S</given-names></name>, <name><surname>Nabil</surname><given-names>F</given-names></name>, <name><surname>Rami</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Effect of remote ischemic preconditioning on serum troponin T level following elective percutaneous coronary intervention</article-title>. <source>Catheter Cardiovasc Interv</source>
<volume>82</volume>: <fpage>E647</fpage>&#x02013;<lpage>653</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ccd.24825">10.1002/ccd.24825</ext-link></comment>
<pub-id pub-id-type="pmid">23404916</pub-id></mixed-citation></ref><ref id="pone.0194623.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Hoole</surname><given-names>SP</given-names></name>, <name><surname>Heck</surname><given-names>PM</given-names></name>, <name><surname>Sharples</surname><given-names>L</given-names></name>, <name><surname>Khan</surname><given-names>SN</given-names></name>, <name><surname>Duehmke</surname><given-names>R</given-names></name>, <name><surname>Densem</surname><given-names>CG</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Cardiac Remote Ischemic Preconditioning in Coronary Stenting (CRISP Stent) Study: a prospective, randomized control trial</article-title>. <source>Circulation</source>
<volume>119</volume>: <fpage>820</fpage>&#x02013;<lpage>827</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCULATIONAHA.108.809723">10.1161/CIRCULATIONAHA.108.809723</ext-link></comment>
<pub-id pub-id-type="pmid">19188504</pub-id></mixed-citation></ref><ref id="pone.0194623.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Davies</surname><given-names>WR</given-names></name>, <name><surname>Brown</surname><given-names>AJ</given-names></name>, <name><surname>Watson</surname><given-names>W</given-names></name>, <name><surname>McCormick</surname><given-names>LM</given-names></name>, <name><surname>West</surname><given-names>NE</given-names></name>, <name><surname>Dutka</surname><given-names>DP</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Remote ischemic preconditioning improves outcome at 6 years after elective percutaneous coronary intervention: the CRISP stent trial long-term follow-up</article-title>. <source>Circ Cardiovasc Interv</source>
<volume>6</volume>: <fpage>246</fpage>&#x02013;<lpage>251</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCINTERVENTIONS.112.000184">10.1161/CIRCINTERVENTIONS.112.000184</ext-link></comment>
<pub-id pub-id-type="pmid">23696599</pub-id></mixed-citation></ref><ref id="pone.0194623.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Isono</surname><given-names>T</given-names></name>, <name><surname>Kamihata</surname><given-names>H</given-names></name>, <name><surname>Sutani</surname><given-names>Y</given-names></name>, <name><surname>Motohiro</surname><given-names>M</given-names></name>, <name><surname>Yamamoto</surname><given-names>S</given-names></name>, <name><surname>Kyoui</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Nicorandil suppressed myocardial injury after percutaneous coronary intervention</article-title>. <source>Int J Cardiol</source>
<volume>123</volume>: <fpage>123</fpage>&#x02013;<lpage>128</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcard.2006.11.219">10.1016/j.ijcard.2006.11.219</ext-link></comment>
<pub-id pub-id-type="pmid">17346816</pub-id></mixed-citation></ref><ref id="pone.0194623.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Hirohata</surname><given-names>A</given-names></name>, <name><surname>Yamamoto</surname><given-names>K</given-names></name>, <name><surname>Hirose</surname><given-names>E</given-names></name>, <name><surname>Kobayashi</surname><given-names>Y</given-names></name>, <name><surname>Takafuji</surname><given-names>H</given-names></name>, <name><surname>Sano</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Nicorandil prevents microvascular dysfunction resulting from PCI in patients with stable angina pectoris: a randomised study</article-title>. <source>EuroIntervention</source>
<volume>9</volume>: <fpage>1050</fpage>&#x02013;<lpage>1056</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4244/EIJV9I9A178">10.4244/EIJV9I9A178</ext-link></comment>
<pub-id pub-id-type="pmid">24457276</pub-id></mixed-citation></ref><ref id="pone.0194623.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Matsuo</surname><given-names>H</given-names></name>, <name><surname>Watanabe</surname><given-names>S</given-names></name>, <name><surname>Watanabe</surname><given-names>T</given-names></name>, <name><surname>Warita</surname><given-names>S</given-names></name>, <name><surname>Kojima</surname><given-names>T</given-names></name>, <name><surname>Hirose</surname><given-names>T</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Prevention of no-reflow/slow-flow phenomenon during rotational atherectomy&#x02014;a prospective randomized study comparing intracoronary continuous infusion of verapamil and nicorandil</article-title>. <source>Am Heart J</source>
<volume>154</volume>: <fpage>994</fpage> e991-996. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ahj.2007.07.036">10.1016/j.ahj.2007.07.036</ext-link></comment>
<pub-id pub-id-type="pmid">17967610</pub-id></mixed-citation></ref><ref id="pone.0194623.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Hwang</surname><given-names>J</given-names></name>, <name><surname>Lee</surname><given-names>HC</given-names></name>, <name><surname>Kim</surname><given-names>BW</given-names></name>, <name><surname>Yang</surname><given-names>MJ</given-names></name>, <name><surname>Park</surname><given-names>JS</given-names></name>, <name><surname>Park</surname><given-names>JH</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Effect on periprocedural myocardial infarction of intra-coronary nicorandil prior to percutaneous coronary intervention in stable and unstable angina</article-title>. <source>J Cardiol</source>
<volume>62</volume>: <fpage>77</fpage>&#x02013;<lpage>81</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jjcc.2013.03.017">10.1016/j.jjcc.2013.03.017</ext-link></comment>
<pub-id pub-id-type="pmid">23731922</pub-id></mixed-citation></ref><ref id="pone.0194623.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>SJ</given-names></name>, <name><surname>Kim</surname><given-names>W</given-names></name>, <name><surname>Woo</surname><given-names>JS</given-names></name>, <name><surname>Ha</surname><given-names>SJ</given-names></name>, <name><surname>Kang</surname><given-names>WY</given-names></name>, <name><surname>Hwang</surname><given-names>SH</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Effect of myocardial protection of intracoronary adenosine and nicorandil injection in patients undergoing non-urgent percutaneous coronary intervention: a randomized controlled trial</article-title>. <source>Int J Cardiol</source>
<volume>158</volume>: <fpage>88</fpage>&#x02013;<lpage>92</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcard.2011.01.011">10.1016/j.ijcard.2011.01.011</ext-link></comment>
<pub-id pub-id-type="pmid">21256606</pub-id></mixed-citation></ref><ref id="pone.0194623.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Heusch</surname><given-names>G</given-names></name>, <name><surname>Botker</surname><given-names>HE</given-names></name>, <name><surname>Przyklenk</surname><given-names>K</given-names></name>, <name><surname>Redington</surname><given-names>A</given-names></name>, <name><surname>Yellon</surname><given-names>D</given-names></name> (<year>2015</year>) <article-title>Remote ischemic conditioning</article-title>. <source>J Am Coll Cardiol</source>
<volume>65</volume>: <fpage>177</fpage>&#x02013;<lpage>195</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jacc.2014.10.031">10.1016/j.jacc.2014.10.031</ext-link></comment>
<pub-id pub-id-type="pmid">25593060</pub-id></mixed-citation></ref><ref id="pone.0194623.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Ito</surname><given-names>N</given-names></name>, <name><surname>Nanto</surname><given-names>S</given-names></name>, <name><surname>Doi</surname><given-names>Y</given-names></name>, <name><surname>Kurozumi</surname><given-names>Y</given-names></name>, <name><surname>Natsukawa</surname><given-names>T</given-names></name>, <name><surname>Shibata</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Beneficial effects of intracoronary nicorandil on microvascular dysfunction after primary percutaneous coronary intervention: demonstration of its superiority to nitroglycerin in a cross-over study</article-title>. <source>Cardiovasc Drugs Ther</source>
<volume>27</volume>: <fpage>279</fpage>&#x02013;<lpage>287</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s10557-013-6456-y">10.1007/s10557-013-6456-y</ext-link></comment>
<pub-id pub-id-type="pmid">23722418</pub-id></mixed-citation></ref><ref id="pone.0194623.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Garg</surname><given-names>V</given-names></name>, <name><surname>Hu</surname><given-names>K</given-names></name> (<year>2007</year>) <article-title>Protein kinase C isoform-dependent modulation of ATP-sensitive K+ channels in mitochondrial inner membrane</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>293</volume>: <fpage>H322</fpage>&#x02013;<lpage>332</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1152/ajpheart.01035.2006">10.1152/ajpheart.01035.2006</ext-link></comment>
<pub-id pub-id-type="pmid">17351068</pub-id></mixed-citation></ref><ref id="pone.0194623.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>O'Rourke</surname><given-names>B</given-names></name> (<year>2000</year>) <article-title>Myocardial K(ATP) channels in preconditioning</article-title>. <source>Circ Res</source>
<volume>87</volume>: <fpage>845</fpage>&#x02013;<lpage>855</lpage>. <pub-id pub-id-type="pmid">11073879</pub-id></mixed-citation></ref><ref id="pone.0194623.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Miyoshi</surname><given-names>T</given-names></name>, <name><surname>Ejiri</surname><given-names>K</given-names></name>, <name><surname>Kohno</surname><given-names>K</given-names></name>, <name><surname>Nakahama</surname><given-names>M</given-names></name>, <name><surname>Doi</surname><given-names>M</given-names></name>, <name><surname>Munemasa</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2017</year>) <article-title>Effect of remote ischemia or nicorandil on myocardial injury following percutaneous coronary intervention in patients with stable coronary artery disease: A randomized controlled trial</article-title>. <source>Int J Cardiol</source>
<volume>236</volume>: <fpage>36</fpage>&#x02013;<lpage>42</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcard.2017.02.028">10.1016/j.ijcard.2017.02.028</ext-link></comment>
<pub-id pub-id-type="pmid">28214082</pub-id></mixed-citation></ref><ref id="pone.0194623.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Higuchi</surname><given-names>Y</given-names></name>, <name><surname>Hiro</surname><given-names>T</given-names></name>, <name><surname>Takayama</surname><given-names>T</given-names></name>, <name><surname>Kanai</surname><given-names>T</given-names></name>, <name><surname>Kawano</surname><given-names>T</given-names></name>, <name><surname>Fukamachi</surname><given-names>D</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Impact of coronary plaque burden and composition on periprocedural myocardial infarction and coronary flow reserve after percutaneous coronary intervention</article-title>. <source>International heart journal</source>
<volume>55</volume>: <fpage>391</fpage>&#x02013;<lpage>396</lpage>. <pub-id pub-id-type="pmid">25070121</pub-id></mixed-citation></ref><ref id="pone.0194623.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Cavallini</surname><given-names>C</given-names></name>, <name><surname>Savonitto</surname><given-names>S</given-names></name>, <name><surname>Violini</surname><given-names>R</given-names></name>, <name><surname>Arraiz</surname><given-names>G</given-names></name>, <name><surname>Plebani</surname><given-names>M</given-names></name>, <name><surname>Olivari</surname><given-names>Z</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study</article-title>. <source>European heart journal</source>
<volume>26</volume>: <fpage>1494</fpage>&#x02013;<lpage>1498</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehi173">10.1093/eurheartj/ehi173</ext-link></comment>
<pub-id pub-id-type="pmid">15741227</pub-id></mixed-citation></ref><ref id="pone.0194623.ref027"><label>27</label><mixed-citation publication-type="journal"><collab>Group JCSJW</collab> (<year>2013</year>) <article-title>Guidelines for Elective Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease (JCS 2011) Published in 2012</article-title>. <source>Circulation Journal</source>
<volume>77</volume>: <fpage>1590</fpage>&#x02013;<lpage>1607</lpage>. <pub-id pub-id-type="pmid">23657129</pub-id></mixed-citation></ref><ref id="pone.0194623.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Yamanaka</surname><given-names>T</given-names></name>, <name><surname>Kawai</surname><given-names>Y</given-names></name>, <name><surname>Miyoshi</surname><given-names>T</given-names></name>, <name><surname>Mima</surname><given-names>T</given-names></name>, <name><surname>Takagaki</surname><given-names>K</given-names></name>, <name><surname>Tsukuda</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Remote ischemic preconditioning reduces contrast-induced acute kidney injury in patients with ST-elevation myocardial infarction: a randomized controlled trial</article-title>. <source>Int J Cardiol</source>
<volume>178</volume>: <fpage>136</fpage>&#x02013;<lpage>141</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcard.2014.10.135">10.1016/j.ijcard.2014.10.135</ext-link></comment>
<pub-id pub-id-type="pmid">25464237</pub-id></mixed-citation></ref><ref id="pone.0194623.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Prasad</surname><given-names>A</given-names></name>, <name><surname>Gossl</surname><given-names>M</given-names></name>, <name><surname>Hoyt</surname><given-names>J</given-names></name>, <name><surname>Lennon</surname><given-names>RJ</given-names></name>, <name><surname>Polk</surname><given-names>L</given-names></name>, <name><surname>Simari</surname><given-names>R</given-names></name>, <etal>et al</etal> (<year>2013</year>) <article-title>Remote ischemic preconditioning immediately before percutaneous coronary intervention does not impact myocardial necrosis, inflammatory response, and circulating endothelial progenitor cell counts: a single center randomized sham controlled trial</article-title>. <source>Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography &#x00026; Interventions</source>
<volume>81</volume>: <fpage>930</fpage>&#x02013;<lpage>936</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/ccd.25067">10.1002/ccd.25067</ext-link></comment><pub-id pub-id-type="pmid">22517646</pub-id></mixed-citation></ref><ref id="pone.0194623.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Testa</surname><given-names>L</given-names></name>, <name><surname>Latini</surname><given-names>RA</given-names></name>, <name><surname>Agostoni</surname><given-names>P</given-names></name>, <name><surname>Banning</surname><given-names>AP</given-names></name>, <name><surname>Bedogni</surname><given-names>F</given-names></name> (<year>2009</year>) <article-title>Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery</article-title>. <source>The American journal of cardiology</source>
<volume>103</volume>: <fpage>1622</fpage>&#x02013;<lpage>1623</lpage>.</mixed-citation></ref><ref id="pone.0194623.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JM</given-names></name>, <name><surname>Layland</surname><given-names>J</given-names></name>, <name><surname>Jung</surname><given-names>JH</given-names></name>, <name><surname>Lee</surname><given-names>HJ</given-names></name>, <name><surname>Echavarria-Pinto</surname><given-names>M</given-names></name>, <name><surname>Watkins</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2015</year>) <article-title>Integrated physiologic assessment of ischemic heart disease in real-world practice using index of microcirculatory resistance and fractional flow reserve: insights from the International Index of Microcirculatory Resistance Registry</article-title>. <source>Circ Cardiovasc Interv</source>
<volume>8</volume>: <fpage>e002857</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCINTERVENTIONS.115.002857">10.1161/CIRCINTERVENTIONS.115.002857</ext-link></comment>
<pub-id pub-id-type="pmid">26499500</pub-id></mixed-citation></ref><ref id="pone.0194623.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Murakami</surname><given-names>M</given-names></name>, <name><surname>Iwasaki</surname><given-names>K</given-names></name>, <name><surname>Kusachi</surname><given-names>S</given-names></name>, <name><surname>Hina</surname><given-names>K</given-names></name>, <name><surname>Hirota</surname><given-names>M</given-names></name>, <name><surname>Hirohata</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Nicorandil reduces the incidence of minor cardiac marker elevation after coronary stenting</article-title>. <source>Int J Cardiol</source>
<volume>107</volume>: <fpage>48</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ijcard.2005.02.034">10.1016/j.ijcard.2005.02.034</ext-link></comment>
<pub-id pub-id-type="pmid">16337497</pub-id></mixed-citation></ref><ref id="pone.0194623.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Kawai</surname><given-names>Y</given-names></name>, <name><surname>Hisamatsu</surname><given-names>K</given-names></name>, <name><surname>Matsubara</surname><given-names>H</given-names></name>, <name><surname>Dan</surname><given-names>K</given-names></name>, <name><surname>Akagi</surname><given-names>S</given-names></name>, <name><surname>Miyaji</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Intravenous administration of nicorandil immediately before percutaneous coronary intervention can prevent slow coronary flow phenomenon</article-title>. <source>Eur Heart J</source>
<volume>30</volume>: <fpage>765</fpage>&#x02013;<lpage>772</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/eurheartj/ehp077">10.1093/eurheartj/ehp077</ext-link></comment>
<pub-id pub-id-type="pmid">19276198</pub-id></mixed-citation></ref><ref id="pone.0194623.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>C</given-names></name>, <name><surname>Bulluck</surname><given-names>H</given-names></name>, <name><surname>Fang</surname><given-names>N</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Hausenloy</surname><given-names>DJ</given-names></name> (<year>2017</year>) <article-title>Age and Surgical Complexity impact on Renoprotection by Remote Ischemic Preconditioning during Adult Cardiac Surgery: A Meta analysis</article-title>. <source>Sci Rep</source>
<volume>7</volume>: <fpage>215</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-017-00308-3">10.1038/s41598-017-00308-3</ext-link></comment>
<pub-id pub-id-type="pmid">28303021</pub-id></mixed-citation></ref><ref id="pone.0194623.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Thygesen</surname><given-names>K</given-names></name>, <name><surname>Alpert</surname><given-names>JS</given-names></name>, <name><surname>Jaffe</surname><given-names>AS</given-names></name>, <name><surname>Simoons</surname><given-names>ML</given-names></name>, <name><surname>Chaitman</surname><given-names>BR</given-names></name>, <name><surname>White</surname><given-names>HD</given-names></name> (<year>2012</year>) <article-title>Third universal definition of myocardial infarction</article-title>. <source>Global heart</source>
<volume>7</volume>: <fpage>275</fpage>&#x02013;<lpage>295</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.gheart.2012.08.001">10.1016/j.gheart.2012.08.001</ext-link></comment>
<pub-id pub-id-type="pmid">25689940</pub-id></mixed-citation></ref><ref id="pone.0194623.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>J</given-names></name>, <name><surname>Xu</surname><given-names>JP</given-names></name>, <name><surname>Zhao</surname><given-names>XZ</given-names></name>, <name><surname>Sun</surname><given-names>XJ</given-names></name>, <name><surname>Xu</surname><given-names>ZW</given-names></name>, <name><surname>Song</surname><given-names>SJ</given-names></name> (<year>2014</year>) <article-title>Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention</article-title>. <source>Cardiology</source>
<volume>127</volume>: <fpage>133</fpage>&#x02013;<lpage>139</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1159/000355574">10.1159/000355574</ext-link></comment>
<pub-id pub-id-type="pmid">24335026</pub-id></mixed-citation></ref><ref id="pone.0194623.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Zografos</surname><given-names>TA</given-names></name>, <name><surname>Katritsis</surname><given-names>GD</given-names></name>, <name><surname>Tsiafoutis</surname><given-names>I</given-names></name>, <name><surname>Bourboulis</surname><given-names>N</given-names></name>, <name><surname>Katsivas</surname><given-names>A</given-names></name>, <name><surname>Katritsis</surname><given-names>DG</given-names></name> (<year>2014</year>) <article-title>Effect of one-cycle remote ischemic preconditioning to reduce myocardial injury during percutaneous coronary intervention</article-title>. <source>The American journal of cardiology</source>
<volume>113</volume>: <fpage>2013</fpage>&#x02013;<lpage>2017</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.amjcard.2014.03.043">10.1016/j.amjcard.2014.03.043</ext-link></comment>
<pub-id pub-id-type="pmid">24793669</pub-id></mixed-citation></ref><ref id="pone.0194623.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Luo</surname><given-names>SJ</given-names></name>, <name><surname>Zhou</surname><given-names>YJ</given-names></name>, <name><surname>Shi</surname><given-names>DM</given-names></name>, <name><surname>Ge</surname><given-names>HL</given-names></name>, <name><surname>Wang</surname><given-names>JL</given-names></name>, <name><surname>Liu</surname><given-names>RF</given-names></name> (<year>2013</year>) <article-title>Remote ischemic preconditioning reduces myocardial injury in patients undergoing coronary stent implantation</article-title>. <source>The Canadian journal of cardiology</source>
<volume>29</volume>: <fpage>1084</fpage>&#x02013;<lpage>1089</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cjca.2012.11.022">10.1016/j.cjca.2012.11.022</ext-link></comment>
<pub-id pub-id-type="pmid">23414904</pub-id></mixed-citation></ref><ref id="pone.0194623.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Lavi</surname><given-names>S</given-names></name>, <name><surname>D'Alfonso</surname><given-names>S</given-names></name>, <name><surname>Diamantouros</surname><given-names>P</given-names></name>, <name><surname>Camuglia</surname><given-names>A</given-names></name>, <name><surname>Garg</surname><given-names>P</given-names></name>, <name><surname>Teefy</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Remote ischemic postconditioning during percutaneous coronary interventions: remote ischemic postconditioning-percutaneous coronary intervention randomized trial</article-title>. <source>Circulation Cardiovascular interventions</source>
<volume>7</volume>: <fpage>225</fpage>&#x02013;<lpage>232</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1161/CIRCINTERVENTIONS.113.000948">10.1161/CIRCINTERVENTIONS.113.000948</ext-link></comment>
<pub-id pub-id-type="pmid">24692535</pub-id></mixed-citation></ref><ref id="pone.0194623.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Zeitouni</surname><given-names>M</given-names></name>, <name><surname>Silvain</surname><given-names>J</given-names></name>, <name><surname>Guedeney</surname><given-names>P</given-names></name>, <name><surname>Kerneis</surname><given-names>M</given-names></name>, <name><surname>Yan</surname><given-names>Y</given-names></name>, <name><surname>Overtchouk</surname><given-names>P</given-names></name>, <etal>et al</etal> (<year>2018</year>) <article-title>Periprocedural myocardial infarction and injury in elective coronary stenting</article-title>. <source>European heart journal</source>.</mixed-citation></ref><ref id="pone.0194623.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>X</given-names></name>, <name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Luo</surname><given-names>S</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>, <name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>Yu</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2014</year>) <article-title>Effect of remote ischemic preconditioning in the elderly patients with coronary artery disease with diabetes mellitus undergoing elective drug-eluting stent implantation</article-title>. <source>Angiology</source>
<volume>65</volume>: <fpage>660</fpage>&#x02013;<lpage>666</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/0003319713507332">10.1177/0003319713507332</ext-link></comment>
<pub-id pub-id-type="pmid">24163121</pub-id></mixed-citation></ref></ref-list></back></article>